United States: Three new studies presented at Digestive Disease Week 2024 analyzed real-world patient data to evaluate the frequency of gastrointestinal adverse effects, such as gastroparesis, in users of common anti-obesity and diabetes medications. These medications include GLP-1 receptor agonists, ...